Eshelman Ventures Leads and Closes Series A Round in Asepticys, Inc., a Development Stage Company Focused on Developing Novel Medical Disinfection Solutions.

Share Article

Asepticys is developing new generation of chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens.

At a time when the medical community, CDC and FDA are closely following public health issues in these areas and considering revisions to applicable standards, we believe this is the game-changer the contact lens solution market has been anticipating.

Asepticys, Inc., is pleased to announce the closing of its series A round of financing with Eshelman Ventures, LLC in Wilmington, NC. “Eshelman Ventures is excited at the tremendous opportunity that Asepticys brings to the market, with truly disruptive potential in the Contact Lens Solutions market as well as numerous other applications in the health and wellness verticals’” says Fred Eshelman.

Asepticys is developing a new generation of chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens and clinically beneficial in numerous medical and consumer healthcare applications.

The medical disinfection solutions contain a unique combination of sterilizing agents, creating a multiple stressor environment that kills and deactivates pathogenic organisms across all microbial kingdoms. This approach is materially different than selective disinfection using either single or dual stressors (e.g., chlorhexidine derivatives), which is currently the standard of care in medical/clinical healthcare. The disinfection solutions are minimally reactogenic and gentle enough for numerous clinical applications including topical skin disinfection, ophthalmologic, surgical, urology catheter, venous catheter and needleless IV connectors, and trauma, wound and burn site maintenance.

The disinfection solutions have been specifically engineered for clinical use and could dramatically reduce hospital-acquired and consumer healthcare-related infection, as well as improve patient outcome via reduction of nosocomial infection in postsurgical/treatment maintenance while in hospital.  According to Chad Roy, CEO, Asepticys, Inc., “At a time when the medical community, CDC and FDA are closely following public health issues in these areas and considering revisions to applicable standards, we believe this is the game-changer the contact lens solution market has been anticipating for over 30 years. This will disrupt and change the game not only in the contact lens solutions market, but in numerous applications around the world requiring sterilization.”

About Eshelman Ventures

Eshelman Ventures LLC, founded by Fred Eshelman was founded as an investment company primarily interested in private healthcare companies. Located in Wilmington, NC, Dr. Eshelman previously founded and served as CEO and Executive Chairman of Pharmaceutical Product Development prior to its sale to private equity interests as well an a number of other companies. For more information on Eshelman Ventures LLC and its investment portfolio visit http://www.eshelmanventures.com

About Asepticys, Inc.

Asepticys is developing new generation chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens and clinically beneficial in numerous medical and consumer healthcare applications.

We are currently focused on development of a multipurpose contact lens disinfection solution (MPDS) to be used regularly as a broad-spectrum sterilizer for daily use lens. Our solution is gentle enough to be used daily, requires minutes for complete sterilization of the lens, and is isotonically balanced for comfort. Also, because of unique combination of sterilants in our formulation, the risk of unwanted biofilm formation in cleaning/storage CL containers is essentially eliminated. For more information on Asepticys visit http://www.asepticys.com

                                                                                     ###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Crawford
Visit website